Malcolm Gottesman

639 total citations
16 papers, 261 citations indexed

About

Malcolm Gottesman is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Malcolm Gottesman has authored 16 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 4 papers in Neurology. Recurrent topics in Malcolm Gottesman's work include Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (5 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Malcolm Gottesman is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (5 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Malcolm Gottesman collaborates with scholars based in United States. Malcolm Gottesman's co-authors include Lauren Krupp, Ilya Kister, Lana Zhovtis Ryerson, Leigh Charvet, Marshall J. Keilson, Nada Abou-Fayssal, Jonathan Howard, Josef Gutman, Patricia K. Coyle and Bianca Weinstock‐Guttman and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Journal of Neurology.

In The Last Decade

Malcolm Gottesman

16 papers receiving 253 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Malcolm Gottesman United States 9 183 104 94 60 26 16 261
Guido Ahle France 5 281 1.5× 241 2.3× 254 2.7× 83 1.4× 34 1.3× 7 430
Mathilde Goudot France 4 262 1.4× 225 2.2× 254 2.7× 85 1.4× 31 1.2× 5 388
Lluís Ramió Torrentà Spain 7 147 0.8× 115 1.1× 29 0.3× 29 0.5× 9 0.3× 10 245
Elizabeth Crabtree United States 7 235 1.3× 97 0.9× 19 0.2× 34 0.6× 32 1.2× 9 389
Arnfin Bergmann Germany 10 161 0.9× 37 0.4× 23 0.2× 51 0.8× 16 0.6× 30 310
Marguerite Duggan Ireland 11 285 1.6× 64 0.6× 12 0.1× 39 0.7× 27 1.0× 14 350
Giorgia Camera Italy 9 30 0.2× 207 2.0× 85 0.9× 17 0.3× 25 1.0× 12 288
Owain Williams United Kingdom 5 223 1.2× 90 0.9× 12 0.1× 62 1.0× 28 1.1× 7 286
Christine Dhillon Germany 7 30 0.2× 30 0.3× 53 0.6× 41 0.7× 9 0.3× 9 246
Aníbal Chertcoff Argentina 8 82 0.4× 59 0.6× 14 0.1× 10 0.2× 9 0.3× 22 133

Countries citing papers authored by Malcolm Gottesman

Since Specialization
Citations

This map shows the geographic impact of Malcolm Gottesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Gottesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Gottesman more than expected).

Fields of papers citing papers by Malcolm Gottesman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Gottesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Gottesman. The network helps show where Malcolm Gottesman may publish in the future.

Co-authorship network of co-authors of Malcolm Gottesman

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm Gottesman. A scholar is included among the top collaborators of Malcolm Gottesman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm Gottesman. Malcolm Gottesman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Jakimovski, Dejan, Katelyn Kavak, Patricia K. Coyle, et al.. (2023). Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium. Journal of Neurology. 271(2). 711–722. 5 indexed citations
2.
Jakimovski, Dejan, Katelyn Kavak, Malcolm Gottesman, et al.. (2023). Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study. Journal of the Neurological Sciences. 455. 122781–122781. 1 indexed citations
3.
Jakimovski, Dejan, Katelyn Kavak, Timothy Coetzee, et al.. (2022). Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC). Multiple Sclerosis Journal. 29(6). 753–756. 8 indexed citations
4.
Jakimovski, Dejan, Katelyn Kavak, Caila B. Vaughn, et al.. (2021). Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders. 57. 103406–103406. 18 indexed citations
5.
Kister, Ilya, Leigh Charvet, Jonathan Howard, et al.. (2020). COVID-19 outcomes in MS. Neurology Neuroimmunology & Neuroinflammation. 7(5). 115 indexed citations
6.
Gottesman, Malcolm, et al.. (2019). Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate. Surgical Neurology International. 10. 59–59. 12 indexed citations
7.
Vaughn, Caila B., Katelyn Kavak, Katia Noyes, et al.. (2017). Self-reported fatigue and lower limb problems predictive of conversion to secondary progressive multiple sclerosis in an aging sample of patients (S10.004). Neurology. 88(16_supplement). 2 indexed citations
8.
Zivadinov, Robert, Diane L. Cookfair, Lauren Krupp, et al.. (2016). Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology. 16(1). 102–102. 13 indexed citations
9.
Kavak, Katelyn, Barbara Teter, Jesper Hagemeier, et al.. (2014). Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Multiple Sclerosis Journal. 21(7). 858–865. 41 indexed citations
10.
Epstein, Nancy E. & Malcolm Gottesman. (2014). Few patients with neurodegenerative disorders require spinal surgery. Surgical Neurology International. 5(4). 81–81. 5 indexed citations
11.
Gladstone, Douglas E., Robert G. Peyster, E. Baron, et al.. (2010). High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis: 2-Year Follow-up (Investigational New Drug No. 65863). American Journal of Therapeutics. 18(1). 23–30. 8 indexed citations
12.
Gottesman, Malcolm, et al.. (2010). An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Multiple Sclerosis Journal. 17(2). 250–253. 11 indexed citations
13.
Lam, Sum, et al.. (2008). Interferon-β1bfor the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology. 4(8). 1111–1117. 4 indexed citations
14.
Gottesman, Malcolm, et al.. (1999). Tissue plasminogen activator for acute stroke in everyday clinical practice. Journal of Stroke and Cerebrovascular Diseases. 8(5). 291–294. 5 indexed citations
15.
Gottesman, Malcolm, et al.. (1996). Cardiac Arrest Caused by Trigeminal Neuralgia. Headache The Journal of Head and Face Pain. 36(6). 392–394. 4 indexed citations
16.
Sands, George H., Eric Muñoz, Malcolm Gottesman, Katherine Mulloy, & Lauren A. Wise. (1988). Neurology, age, hospital costs, and DRGs. Neurology. 38(4). 655–655. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guido Ahle Breakdown of academic impact, for papers by Mathilde Goudot Breakdown of academic impact, for papers by Lluís Ramió Torrentà Breakdown of academic impact, for papers by Elizabeth Crabtree Breakdown of academic impact, for papers by Arnfin Bergmann Breakdown of academic impact, for papers by Marguerite Duggan Breakdown of academic impact, for papers by Giorgia Camera Breakdown of academic impact, for papers by Owain Williams Breakdown of academic impact, for papers by Christine Dhillon Breakdown of academic impact, for papers by Aníbal Chertcoff
Rankless by CCL
2026